Table 2.
Summary of anti-EGFR therapy for colorectal cancer (CRC).
| Regimen | Target population | Design | Treatment | Registration number | Reference |
|---|---|---|---|---|---|
| Cetuximab | mCRC | Phase II | Cetuximab + FOLFOX-6 | NCT01051167 | (216) |
| mCRC | Phase III | Chemotherapy + Bevacizumab Chemotherapy + Bevacizumab + Cetuximab |
NCT00208546 | (221) | |
| mCRC | Phase III | Cetuximab + FOLFIRI FOLFIRI |
NCT00154102 | (213) | |
| Panitumumab | mCRC | Phase III | Panitumumab + FOLFOX4 FOLFOX4 |
NCT00364013 | (218) |
| mCRC | Phase II | Panitumumab + FOLFOXIFI FOLFOXIFI |
NCT01328171 | (219) |